Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | LAP3 | P28838 | 4/20 | 0.35 |
| ▸ | ANPEP | P15144 | 3/20 | 0.35 |
| ▸ | ACP3 | P15309 | 2/20 | 0.34 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.33 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.33 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.33 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8618813 | 0.94 | PPARA (0.37) | PPARALAP3ANPEPPPARGFDFT1 | |
| SCHEMBL8947039 | 0.90 | LAP3 (0.36) | LAP3ANPEPACP3ERAP1ERAP2 | |
| SCHEMBL8947013 | 0.89 | HTR2A (0.35) | LAP3ANPEPACP3ERAP1ERAP2 | |
| SCHEMBL8824820 | 0.87 | LAP3 (0.33) | PPARALAP3ANPEPACP3PPARG | |
| SCHEMBL8947080 | 0.84 | AKR1C3 (0.35) | PPARALAP3ANPEPACP3PPARG | |
| SCHEMBL8623433 | 0.84 | SCN4A (0.39) | PPARALAP3ANPEPACP3PPARG | |
| SCHEMBL9167366 | 0.84 | ADRA2C (0.38) | HTR1AADRA2AADRA2BADRA2CLAP3 | |
| SCHEMBL8620802 | 0.83 | PPARG (0.42) | PPARAPPARGFDFT1 | |
| SCHEMBL8619900 | 0.83 | PPARA (0.36) | PPARAPPARG | |
| SCHEMBL8623169 | 0.82 | FDFT1 (0.40) | PPARAPPARGFDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5712396-A | PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS | MAGNIN DAVID R (US) | 1998-01-27 | — | — | US | claimed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | claimed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | claimed |
| US-5712396-A | PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS | MAGNIN DAVID R (US) | 1998-01-27 | — | — | US | disclosed |
| US-5567841-A | ANTICHOLESTEROL AGENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | disclosed |